MRI contrast developer Epix Medical reported revenues of $1.7 million in its first quarter, up 35% compared with the $1.1 million posted in the same period last year. For the period (end-March 31), the Cambridge, MA-based firm had a net loss of $5 million, compared with a net loss of $9.3 million for the first quarter of 2000.
Epix remains focused on the successful completion of enrollment in phase III clinical trial for its MS-325 agent, according to CEO Michael Webb. The trials will determine the efficacy of the agent for the diagnosis of peripheral vascular disease.
By AuntMinnie.com staff writersApril 27, 2001
Related Reading
Epix, InSightec, Brigham and Women's team up, March 12, 2001
Epix loss widens in 2000, February 16, 2001
Schering gains Japanese rights to Epix’s MS-325, January 9, 2001
Copyright © 2001 AuntMinnie.com
